Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women

British Journal of Haematology

Volumn 100, Issue 3, 1998, Pages 577-581

  Frohlich M ^a,e   Schunkert, H ^b   Hense, H W ^c   Tropitzsch, A ^a   Hendricks, P ^c   Doring A ^d   Riegger, G A J ^b   Koenig, W ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Fibrinogen; Hormone replacement therapy; Plasma viscosity

Indexed keywords

ESTROGEN; FIBRINOGEN; PROGESTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; ESTROGEN THERAPY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLASMA VISCOSITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD VISCOSITY; CORONARY DISEASE; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FIBRINOGEN; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGESTERONE;

EID: 0031839982     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00594.x     Document Type: Article

References (21)

1. Akahoshi, M. Soda, M., Nakashima, K., Shimaoka, K., Seto, S. & Yano, K. (1996) Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation, 94, 61-66.
2. Barrett-Connor, E. & Bush, T.L. (1991) Estrogen and coronary heart disease in women. Journal of the American Medical Association, 265, 1861-1867.
3. Baumann, H. & Gauldie, J. (1994) The acute phase response. Immunology Today, 15, 74-80.
4. Boschetti, C., Cortellaro, M., Nenicioni, T., Bertolli, V. Volpe, D.A. & Zanussi, C. (1991) Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thrombosis Research, 62, 1-8.
5. Ernst, K. & Koenig, W. (1997) Fibrinogen and cardiovascular risk. Vascular Medicine, 2, 115-125.
6. Gordon, E.M., Williams, S.R., Frenchek, B., Mazur, C.A. & Speroff, L. (1988) Dose-dependent effects of postmenopausal oestrogen and progestin on antithrombin III and factor XII. Journal of Laboratory and Clinical Medicine, 111, 52-56.
7. Keil, U., Stieber, J., Döring, A., Chambless, L., Härtel, U., Filipiak, B., Hense, H.W., Tietze, M. & Gostomzyk, J.G. (1988) The cardiovascular risk factor profile in the study area Augsburg: results from the first MONICA survey 1984/1985. Acta Medica Scandinavica. 728, (Suppl.), 119-128.
8. Krobot, K., Hense, H.W., Cremer, P., Eberle, E. & Keil, U. (1992) Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex: results from the second MONICA Augsburg Survey 1989/1990. Arteriosclerosis and Thrombosis, 12, 780-788.
9. Matthews, K.A., Meilahn, E., Kuller, L.H., Kelesey, S.F., Gaggiula, A.W. & Wing, R.R. (1989) Menopause and risk factors for coronary heart disease. New England Journal of Medicine, 321, 641-646.
10. Matthews, R.R., Meilahn, E.N. & Plantinga, A. (1996) Prior to use of oestrogen replacement therapy, are users healthier than nonusers? American Journal of Epidemiology, 143, 971-978.
11. Meade, T.W., Cooper, J.A., Chakrabarti, R., Miller, G.J., Stirling, Y. & Howarth, D.J. (1996) Fibrinolytic activity and clotting factors in ischaemic heart disease in women. British Medical Journal, 312, 1581.
12. Meade, T.W., Dyer, S., Howarth, D.J., Imeson, J.D. & Stirling, Y. (1990) Antithrombin III and procoagulant activity: sex differences and effects of the menopause. British Journal of Haematology, 74, 77-81.
13. Munro, J.M. & Cotran, R.S. (1988) The pathogenesis of atherosclerosis: atherogenesis and inflammation. Laboratory Investigation, 58, 249-261.
14. Nabulsi, A.A., Folsom, A.R., White, A., Patsch, W., Heiss, G., Wu, K.K. & Szklo, M. (1993) Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. New England Journal of Medicine, 328, 1069-1075.
15. Pepys, M.B. & Baltz, M.L. (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (Pentraxins) and serum amyloid A protein. Advances in Immunology, 34, 141-211.
16. Sack, M.N., Reader, D.J. & Cannon, R.O., III (1994) Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet, 343, 269-270.
17. Salomaa, V., Rasi, V., Pekkanen, J., Vahtera, E., Jauhiainen, M., Vartiainen, E., Ehnholm, C., Tuomilehto, J. & Myllyla, G. (1995) Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors: the FINRISK Hemostasis Study. Arteriosclerosis. Thrombosis and Vascular Biology, 15, 1549-1555.
18. Sweetnam, P.M., Thomas, H.F., Yarnell, J.W.G., Beswick, A.D., Baker, I.A. & Elwood, P.C. (1996) Fibrinogen, viscosity and the 10-year incidence of ischemic heart disease: the Caerphilly and Speedwell Studies. European Heart Journal, 17, 1814-1820.
19. The Writing Group for the PEPI Trial (1995) Effects of oestrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Journal of the American Medical Association, 273, 199-208.
20. WHO MONICA Project (1989) WHO MONICA Project: objectives and design. International Journal of Epidemiology, 18, (Suppl. 1), 29-57.
21. WHO-MONICA-Project Principal Investigators (1988) The World Health Organisation Monica Project (Monitoring trends and determinants in cardiovascular disease): a major international collaboration. Journal of Clinical Epidemiology, 41, 105-114.